1. 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). (September 2015) Authors: Shinozaki, E.; Laurent, S.; Gravalos, C.; Benavides, M.; Munoz, F. Longo; Mizuguchi, H.; Wahba, M.; Ychou, M.; Ciardiello, F.; Siena, S.; Yamaguchi, K.; Muro, K.; Denda, T.; Tsuji, Y; Loehrer, P; Lenz, H.J.; Tebbutt, N.; Mayer, R.J.; Van Cutsem, E.; Ohtsu, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO-1207 Stereotactic radiotherapy and MR-guided adaptive techniques for locally advanced pancreatic cancer. (August 2021) Authors: Ermongkonchai, T.; Khor, R.; Muralidharan, V.; Tebbutt, N.; Lim, K.; Kutaiba, N.; Ng, S.P. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S1001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗